GLP-1s Have Increased Risks for Older Patients

By Wayne Persky

An online article that was recently posted on Medscape discussed some issues that we should be aware of if we are older than 65, especially if we are considering using any of the GLP-1 receptor agonists (Lambrrg, E. (2026, February 3).1

GLP-1 receptor agonists such as semaglutide and tirzepatide have become among the most widely requested medications for weight loss and diabetes management. They can improve blood sugar control, reduce cardiovascular risk, and produce meaningful weight loss. However, in adults over age 65, the risk-benefit balance fundamentally changes.

Here's why:

​Aging brings several baseline vulnerabilities that interact dangerously with GLP-1 medications. Older adults experience reduced muscle mass and strength (sarcopenia), declining bone density, lower thirst response and kidney reserve, increased fall risk, higher rates of polypharmacy (commonly defined as the concurrent use of five or more medications ), and higher prevalence of frailty and malnutrition.
​
GLP-1 medications amplify several of these vulnerabilities because they reduce appetite, slow stomach emptying, promote rapid weight loss, and cause gastrointestinal side effects. The result is that older adults are far more prone to complications from the same effects that younger adults tolerate without difficulty.

The main high risk issues are:

Accelerated muscle loss
This is arguably the single most important concern. Weight loss from GLP-1 drugs does not selectively remove fat—it also reduces lean body mass, including muscle. After age 65, muscle loss accelerates naturally, and muscle is critical for balance, mobility, independence, fall prevention, and metabolic health. Rapid weight loss in older adults can push patients from independent to frail to fall-prone with surprising speed.

This progression leads to falls, hospitalization, disability, and loss of independence. Clinicians increasingly emphasize resistance training and high protein intake specifically to counter this risk. Unfortunately, many older patients on GLP-1 medications do not receive this guidance.

Bone loss and fracture risk
Rapid weight loss reduces the mechanical loading that keeps bones strong through reduced stimulation of bone formation, disruption of bone mineral balance, and loss of the muscle forces that protect bone. Evidence shows that older adults with diabetes using GLP-1 medications had approximately 12% higher fracture risk than those using other diabetes drugs, and hip fractures were more common in clinical trials of semaglutide.

This is especially concerning for postmenopausal women, patients with osteopenia or osteoporosis, and anyone with a history of falls. A hip fracture in an older adult is a major life-changing event, typically associated with high morbidity and mortality.

Dehydration and kidney injury
GLP-1 medications commonly cause nausea, vomiting, diarrhea, and reduced thirst and appetite. Older adults already have reduced thirst sensation, reduced kidney reserve, and higher baseline risk of dehydration. Even mild gastrointestinal symptoms can lead to severe dehydration, acute kidney injury, and hospitalization. This is one of the most common serious complications in older patients using GLP-1 drugs.

Moderate but still important risks:

Malnutrition from appetite suppression
Older adults often tend to have a reduced appetite to begin with, and when using this class of drugs they may over-restrict calories once appetite drops, leading to protein deficiency, vitamin and mineral deficiencies, worsening frailty, immune suppression, and slower healing. Experts now recommend 60 to 90 grams of protein daily, dietitian involvement, and close nutritional monitoring (when using these drugs). This risk is often underestimated, but it can have profound consequences on our functional independence.

Hypoglycemia when GLP-1s are combined with other diabetes drugs
GLP-1 drugs alone rarely cause low blood sugar, but the risk rises significantly when combined with insulin or sulfonylureas. Older adults are especially vulnerable to hypoglycemia, which can cause falls, confusion, cardiac arrhythmias, and hospitalization. Medication regimens often need careful adjustment when GLP-1 therapy begins.

Neurologic symptoms and dizziness
Dizziness is one of the most common neurologic side effects in older users, and it can be caused by dehydration, orthostatic hypotension (a sudden, significant drop in blood pressure upon standing or changing positions), reduced calorie intake, or rapid weight loss. In older adults, dizziness significantly increases fall risk, creating a dangerous cycle where medication side effects directly threaten the independence the patient is trying to preserve.

Why older patients require closer monitoring:

Experts recommend regular lab monitoring (especially of kidney function), slower dose escalation, nutrition counseling, hydration goals of approximately 64 ounces daily, resistance training several times weekly, and avoiding compounded versions of GLP-1 drugs. Dose escalation should never occur until the current dose is well tolerated.

When GLP-1 drugs may not be appropriate:

Absolute contraindications include personal or family history of medullary thyroid cancer, MEN2 syndrome, severe gastroparesis (delayed stomach emptying) or bowel obstruction, and end-stage renal disease or dialysis. Strong relative contraindications include moderate to severe dementia, chronic kidney disease stage 4, baseline frailty or sarcopenia, and severe osteoporosis or frequent falls. These conditions dramatically increase complication risk and may make GLP-1 therapy more harmful than helpful.

The Bottom Line:

GLP-1 medications can be powerful and beneficial, even in older adults, but in this population the biggest risks are not cosmetic or metabolic—they are functional and structural. Muscle loss leads to frailty and falls. Bone loss leads to fractures. Dehydration leads to kidney injury. Malnutrition leads to decline and disability.

For older adults, the key question is not simply "Will this help me lose weight?" It is "Will this help me stay strong, stable, and independent?" When used in carefully selected patients with close monitoring, nutrition support, resistance training, and attention to hydration and protein intake, GLP-1 medications can be helpful. Without that supervision, they can unintentionally accelerate the very problems aging patients most want to avoid — loss of strength, loss of mobility, and loss of independence.

Reference:

1. Lambrrg, E. (2026, February 3). Older Patients Have Specific Risks for GLP-1 Use. Medscape, Retrieved from, https://www.medscape.com/viewarticle/older-patients-have-specific-risks-glp-1-use-2026a10003bb